Lipocine Inc. (LPCN) PT Set at $11.00 by Canaccord Genuity
Lipocine Inc. (NASDAQ:LPCN) has been given a $11.00 price target by Canaccord Genuity in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 144.99% from the stock’s previous close.
Several other research analysts also recently weighed in on LPCN. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Lipocine in a research note on Wednesday, April 26th. Roth Capital set a $38.00 target price on Lipocine and gave the stock a “buy” rating in a research note on Tuesday, June 20th.
Shares of Lipocine (NASDAQ:LPCN) traded up 1.58% on Monday, hitting $4.49. The stock had a trading volume of 102,737 shares. The company’s market cap is $86.48 million. Lipocine has a 12 month low of $3.03 and a 12 month high of $5.90. The company’s 50 day moving average price is $4.36 and its 200-day moving average price is $3.96.
Lipocine (NASDAQ:LPCN) last announced its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.04. On average, analysts expect that Lipocine will post ($1.12) earnings per share for the current year.
A number of hedge funds have recently modified their holdings of LPCN. California State Teachers Retirement System purchased a new stake in shares of Lipocine during the second quarter worth approximately $106,000. Wells Fargo & Company MN purchased a new stake in shares of Lipocine during the third quarter worth approximately $122,000. KCG Holdings Inc. boosted its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 7,219 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Lipocine during the second quarter worth approximately $173,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Lipocine during the first quarter worth approximately $226,000. 38.88% of the stock is owned by institutional investors.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.